.Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L02B_HormoneAntagonistsAndRelatedAgents.L02BG06_Exemestane.Exemestane .Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L02B_HormoneAntagonistsAndRelatedAgents.L02BG06_Exemestane.Exemestane| name: | Exemestane |
| ATC code: | L02BG06 | route: | oral |
| n-compartments | 1 |
Exemestane is a steroidal aromatase inhibitor used in the treatment of hormone receptor-positive breast cancer, primarily in postmenopausal women. It reduces the production of estrogen and is approved for use as adjuvant or advanced treatment for breast cancer.
Pharmacokinetic parameters as observed in healthy postmenopausal females after oral administration of a single 25 mg exemestane dose.
Valle, M, et al., & Verotta, D (2005). A predictive model for exemestane pharmacokinetics/pharmacodynamics incorporating the effect of food and formulation. British journal of clinical pharmacology 59(3) 355–364. DOI:10.1111/j.1365-2125.2005.02335.x PUBMED:https://pubmed.ncbi.nlm.nih.gov/15752382
Zhang, Q, et al., & Jiang, Z (2018). Exploratory clinical study of chidamide, an oral subtype-selective histone deacetylase inhibitor, in combination with exemestane in hormone receptor-positive advanced breast cancer. Chinese journal of cancer research = Chung-kuo yen cheng yen chiu 30(6) 605–612. DOI:10.21147/j.issn.1000-9604.2018.06.05 PUBMED:https://pubmed.ncbi.nlm.nih.gov/30700929